Polaryx Therapeutics, Inc. Common Stock
PLYXNASDAQHealthcareBiotechnology
Previous close
$2.07
−$0.07 · -3.27%
PLYX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
19
Strong Down
Sentiment
59
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePolaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Alex Yang
- Listed since
- Feb 2, 2026
- Employees
- 11
Market position
Day range
Current $2.07
52-week range
Current $2.07
- Open
- $2.14
- Previous close
- $2.14
- Volume
- 108.47K
- 0.6× average
- Average volume
- 182.16K
- Average daily volume
- Market cap
- 103.18M USD
- Beta
- -9.19
- Market reference 1
- 50-day average
- $2.304
- -10.16% below average
- 200-day average
- $4.23
- -51.06% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.65B USD
- P/E (TTM)
- -17.01×
- P/B (TTM)
- 9.14×
- P/S (TTM)
- 0×
- EV / EBITDA
- -183.85×
- Earnings yield
- -0.54%
- Free cash flow yield
- -0.24%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -196.82%
- Return on assets
- -165.77%
- Return on invested capital
- -162.43%
Financial health
- Debt / equity
- 0×
- Current ratio
- 8.55×
Earnings
- Latest fiscal-year EPS
- -0.19
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
PLYX peers
ETFs holding PLYX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research PLYXresearch.disclaimer